RNS Number: 6255 Z Cambridge Cognition Holdings PLC 21 September 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cambridge Cognition Holdings Plc (COG.L) Announced that Richard Bungay will join the Board as a Non-Executive Director with immediate effect. Currently, he is CFO of Diurnal Group plc, the AIM quoted specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. #COG
RNS Number: 8149 Y Cambridge Cognition Holdings PLC 14 September 2020 Cambridge Cognition Holdings Plc. Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, is pleased to announce that Richard Bungay will join the Board as a Non-Executive Director with immediate effect.. Bungay has over 25 years' experience...
RNS Number: 3510 Y Cambridge Cognition Holdings PLC 08 September 2020 Cambridge Cognition Holdings plc. Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, will announce its interim results for the six months to 30 June 2020 on 22 September 2020.. RNS is approved by the Financial Conduct Authority to act as a...
RNS Number: 2451 Y Cambridge Cognition Holdings PLC 07 September 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5271 X Cambridge Cognition Holdings PLC 01 September 2020. £2 m contract for three late phase schizophrenia trials. Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a £2 m contract as the cognitive assessment partner for three late phase clinical trials...
RNS Number: 1978 U Cambridge Cognition Holdings PLC 27 July 2020 Cambridge Cognition Holdings Plc. Result of AGM and Board Changes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0097 T Cambridge Cognition Holdings PLC 15 July 2020. New virtual study with COVID-19 healthcare workers. Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, is collaborating with 4 YouandMe and The Center for International Emergency Medical Services to investigate the utility of wearables...
RNS Number: 0332 S Cambridge Cognition Holdings PLC 03 July 2020. Posting of Annual Report& Notice of AGM. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cambridge Cognition Holdings Plc (COG.L) Announced further contract wins in the first half of 2020, taking the order intake to £4.90 million for the year to date, compared with £2.60 million for the first half of 2019. To date in 2020, the company has signed contracts for four large orders of over £500.00k and ten for between £50.00k and £500.00k, as well as taking many smaller orders. The contracted order book for the company is now at £7.50 million compared to £5.70 million at 31 December 2019. The company will announce its interim results for the six months to 30 June 2020 on 22 September 2020, at which time further guidance on the anticipated outcome for the year will be provided. #COG
RNS Number: 4985 R Cambridge Cognition Holdings PLC 30 June 2020. Annual Report& Notice of AGM. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, is pleased to announce further contract wins in the first half of 2020, taking the order intake to £4.9 m for the year to date, compared with £2.6 m for the first half of 2019. To date in 2020, the Company has signed contracts for four large orders of over £500 k...
RNS Number: 8385 Q Cambridge Cognition Holdings PLC 23 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, announces that on 8 June 2020, the Company granted options over a total of 1,040,041 ordinary shares of 1 pence each in the capital of the Company pursuant to the Company's EMI option scheme and the Company's unapproved option scheme..
RNS Number: 0362 P Cambridge Cognition Holdings PLC 05 June 2020 5 June 2020. Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, is pleased to announce that it will be hosting a Capital Markets Showcase via Webex on 30 June 2020 at 10 am.. RNS is approved by the Financial Conduct Authority to act as a Primary...
Cambridge Cognition Holdings Plc (COG.L) Announced that the company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1 million - the majority of which is expected to be recognised this financial year. #COG
Cambridge Cognition 27.5p £8.6m (COG.L) The Company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1 million - the majority of which is expected to be recognised this financial year. #COG
RNS Number: 9970 N Cambridge Cognition Holdings PLC 27 May 2020. Over £1 million of New Contract Wins. Cambridge Cognition Holdings plc, which develops and markets digital solutions to assess brain health, is pleased to announce that the Company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials,...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    31.17M

Company Profile

The world's leading computerised cognitive assessments and eCOA platform. CANTAB sensitively and objectively measures cognitive function, quantifies levels of performance and impairment, and demonstrates the effectiveness of interventions in brain health. The cloud technology is a cost-effective and non-invasive means of assaying brain function and patient outcomes, aiding and accelerating research and decision-making. CANTAB technology has been used in thousands of clinical trials, health settings and academic institutions, in over 100 countries.

Classification

Market Indices-
Watchlist